Sponsor Overview
Explore verified public information about Servier Pharmaceuticals's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 4 supporting sources.
“An Expanded Access Program, also known as “compassionate use,” is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials.”
“Servier is committed to providing innovative therapeutic solutions to treat and care for patients. Patients who meet certain defined criteria may be eligible to participate in Servier’s clinical trials to access investigational drugs before the drugs have been approved for a current commercial use in the patient’s disease. Servier recognizes that patients and their physicians may believe that a patient with a serious or immediately life-threatening disease could benefit from Servier’s investigational drugs, even if the patient does not qualify for participation in one of Servier’s clinical trials.”
“Through our patient access program, expanded access and government programs including 340B, Servier is ensuring safe access to medicine for all of our patients, committing to affordable and reduced pricing for eligible healthcare organizations and covered entities.”
“Expanded Access is for patients who may be eligible to participate in Servier’s clinical trials to access investigational drugs before the drugs have been approved for a current commercial use in the patient’s disease.”
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Available Therapies via Single-Patient EA Disease/Category-Specific EA Policies/Criteria
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.